Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Yarrow Bioscience.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you.

In the transaction, VYNE shareholders will receive the pre-Merger VYNE stockholders are expected to own approximately 3% of the combined company, and the pre-Merger Yarrow stockholders are expected to own approximately 97% of the combined company. VYNE insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for VYNE by imposing a significant penalty if VYNE accepts a competing bid. We are investigating the conduct of the VYNE board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP                                  Guri AdemiToll Free: (866) 264-3995Fax: (414) 482-8001

SOURCE Ademi LLP